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Abstract
Objective: Beside the major effect of acute thrombus formation, little is known about the interaction of platelets with the coronary
endothelium in an ischaemia–reperfusion situation. The present study was designed to investigate, separately, the consequences of platelet
adhesion and degranulation during myocardial reperfusion. Methods: Isolated guinea pig hearts perfused with Krebs–Henseleit buffer
and performing pressure–volume work were used. We infringed myocardial function by imposing ischaemia 20 min of low-flow
.  .perfusion with 1 mlrmin and 10 min of global ischaemia and reperfusion 15 min with 5 mlrmin . During low-flow perfusion, the
coronary endothelium was stimulated by thrombin before and during infusion of a bolus: 108 washed human platelets" the
 . 8  .  .Arg–Gly–Asp RGD analogon lamifiban, the supernatant of 10 thrombin-stimulated platelets, fibrinogen 2 mM , lamifiban 2 mM or
 .  .Tyrode’s solution control group . The parameter external heart work EHW , determined pre- and postischaemically, served as criterion
for recovery of myocardial function. Additionally, the formation of capillary transudate was measured during the reperfusion phase to
assess coronary permeability. Coronary perfusion pressure was monitored continuously and myocardial production of lactate and
consumption of pyruvate were measured. Electron microscopy of hearts was performed after platelet application to verify platelet
adhesion in the coronary system. Results: Recovery of EHW by hearts without platelet application was 64"3% and was significantly
 .reduced to 49"5% by platelet infusion ns8 each . Infusion of supernatant of thrombin-stimulated platelets did not impair recovery of
 .heart work. In the reperfusion phase 6th–10th min , hearts that either had received platelets or supernatant of platelets exhibited a
 .significantly reduced production of capillary transudate 70 mlrmin vs. 180 mlrmin for the controls . Intracoronary bolus application of
fibrinogen or lamifiban also reduced coronary leak. Coronary perfusion pressure and metabolic parameters were not statistically different
between the groups at any time. Conclusions: Platelet adhesion to the coronary endothelium in a situation of myocardial ischaemia
impairs cardiac recovery, whereas constituents released by platelets may have beneficial effects on the integrity of the coronary
endothelium. In particular, fibrinogen seems to contribute to the permeability reducing effect, possibly by interaction with endothelial
receptors recognising the RGD sequence. q 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Myocardial damage due to coronary occlusion and con-
secutive reperfusion is a rather common clinical occur-
rence. Reperfusion injury may result from unstable angina,
acute thrombolysis after myocardial infarction, percuta-
neous coronary angioplasty, bypass surgery and heart
transplant reperfusion. The relevance of adhesion of poly-
)  .  .Corresponding author. Tel.: q49 89 5996-404; Fax: q49 89
5996-378; E-mail: heindl@ana.med.uni-muenchen.de
 .morphonuclear neutrophils PMN to the activated coro-
nary endothelium was shown for the development of acute
w xpostischaemic damage 1–3 . Beside the possibility of
microcirculatory disturbances, production of oxygen radi-
cals by adherent PMN further deteriorates endothelial in-
w xtegrity and myocardial performance 4 .
With respect to platelets, acute thrombus formation is a
well-known cause of serious reperfusion complication, ad-
hesion of platelets to the coronary endothelium being the
Time for primary review 35 days.
0008-6363r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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initial step. Platelets are a rich source of a wide range of
biologically active materials that are capable of inducing
and augmenting certain inflammatory responses. Such ma-
terials have been shown to be both, preformed mediators
stored in the granula e.g. ADP, fibrinogen, serotonin,
. w xhistamine, PF 5 and newly synthesised agents resulting4
from the perturbation of membrane phospholipids e.g.
.TXA , PGF , PGE . Furthermore, activation of an IgE2 2 a 2
receptor of platelets has been shown to result in the
w xproduction of cytotoxic free radicals 6 . Not surprisingly,
there have been reports that intracoronary infusion of
platelets in an ischaemia–reperfusion situation can induce
w xarrhythmias 7 and impair recovery of heart performance
w x8,9 . However, a number of studies were able to demon-
strate cardioprotective effects of platelet infusion during
w xmyocardial reperfusion 10–12 . These conflicting results
may be due to differences in the experimental protocol
 .e.g. absence or presence of exogenous stimuli and oppos-
ing effects of platelet adhesion and platelet secretion. The
present study was designed to investigate separately the
consequences of adhesion and degranulation of platelets
during myocardial ischaemia and reperfusion. The experi-
ments were performed on isolated perfused hearts of guinea
pigs using washed human platelets in defined number
 8.10 , infused into the coronary system under strictly
standardised conditions.
2. Methods
2.1. Reagents
Iloprost was produced by Schering, Berlin, Germany.
Human thrombin and fibrinogen type I were supplied by
Sigma, St. Louis, USA. Lamifiban, a thyrosine derivate,
was kindly provided by Hoffmann-La Roche, Basel,
Switzerland. Lamifiban is a highly selective non-peptide
GPIIbrIIIa antagonist, which binds to the Arg–Gly–Asp
 .RGD recognition sequence of the GPIIbrIIIa receptor.
Thrombin, fibrinogen and lamifiban were dissolved in
H O for infusion. All other reagents were purchased from2
Merck, Darmstadt, Germany.
2.2. Solutions
 . Phosphate-buffered saline PBS , pH 7.4, contained in
.mmolrl : NaCl, 120; KCl, 2.7; Na HPO , 4.0; KH PO ,2 4 2 4
 .5.0 and 0.1% ethylenediaminetetraacetate EDTA .
Tris-buffered Tyrode’s solution, pH 7.4, contained in
.mmolrl : NaCl, 137; KCl, 2.6; MgCl =6H O, 1.0;2 2
CaCl =2H O, 3.0; Tris, 1.0 and 0.1% glucose.2 2
The composition of the Krebs–Henseleit buffer was as
 .follows in mmolrl : NaCl, 126; NaHCO , 24; KCl, 4.7;3
MgSO =7H O, 0.6; CaCl =2H O, 1.25; KH PO , 1.2;4 2 2 2 2 4
pyruvate, 0.3; glucose, 5.5 and insulin, 5 IUrl.
 .Cellwash Becton Dickinson, San Jose, USA is a phos-
phate-buffered sodium chloride solution for preparation
and analysis of cells in the flow cytometer.
2.3. Platelet preparation
Blood from 9 healthy adult volunteers who had not
ingested aspirin or other anti-inflammatory drugs within
the previous 10 days was drawn by venipuncture into
polypropylene syringes containing EDTA 0.1% and Ilo-
 .prost 50 ngrml final concentrations for anticoagulation.
The blood was centrifuged at 200=g for 15 min. The
platelet rich plasma was separated and centrifuged at 2000
=g for 10 min. After discarding the supernatant, the
pellet of platelets was twice resuspended in PBS and
centrifuged at 10 000=g for 1 min. The washing proce-
dure served to remove Iloprost and plasma components
such as fibrinogen, which mediate platelet aggregation and
would, thereby, confound the interpretation of intracoro-
nary sequestration data. Finally, washed platelets were
resuspended in Tyrode’s solution and adjusted to a final
concentration of 100 000rml. The adjusted platelet suspen-
sions were drawn into a polypropylene syringe immedi-
ately before intracoronary application. To determine
platelet numbers in Tyrode’s solution and in samples of
venous effluent, specimens were counted in triplicate with
a Coulter counter ZM and analysed for distribution of
platelet diameters in a Coulter Channelyzer 256 Coulter
.Electronics, Luton, UK .
2.4. Heart preparation
The care of the animals and all experimental procedures
were in full accordance with German animal protection
laws and officially approved.
Hearts were isolated from male guinea pigs body weight
.200–300 g , following cervical dislocation, without use of
any anticoagulants or anaesthetics. After median thoraco-
tomy and rapid arrest of the beating hearts by superfusion
with ice-cold isotonic saline, the ascending aorta was
cannulated and the hearts were rapidly excised. The iso-
lated organs were perfused in the non-working ‘Langen-
dorff’ mode at 378C with a modified Krebs–Henseleit
buffer, equilibrated with 94.4% O and 5.6% CO pH2 2
.7.40"0.05 for 15–20 min to allow further preparation.
The veins entering the right atrium and the pulmonary
veins were ligated to ensure that the coronary effluent
passed through the pulmonary artery. This vessel was
cannulated to enable collection of the coronary venous
effluent. The left atrium was cannulated through an open-
ing formed by uniting the four pulmonary vein orifices to
allow natural filling of the atrium and contraction of the
w xleft atrial appendage 13 . The perfusion pressure was
continuously monitored with a pressure transducer FMI
.GmbH, Egelsbach, Germany and aortic and coronary
flows were recorded with an ultrasonic flow meter Trans-
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.sonic Systems, Ithaca, USA . Heart rate was derived from
the phasic perfusion pressure signal.
The hearts performed pressure–volume work at a left
atrial filling pressure of 8.8 mmHg and a mean aortic
pressure of 59 mmHg. Pre- and afterload were regulated
by resistance valves in the filling system of the left atrium
and the outflow system of the aorta, respectively.
2.5. Experimental protocol for working hearts
The perfusion protocol is outlined in Fig. 1. After an
initial 20 min work phase, W , the hearts were perfused in1
a non-working, constant flow mode. After closure of both
the in- and outflow valves of the hydrostatically controlled
perfusion system, a pump supplied a constant flow ‘retro-
gradely’ into the coronary system via the aortic cannula. A
reduced coronary flow of 1 mlrmin was established for 20
min to mimic ‘low-flow’ perfusion. Thereafter, a global
stopped-flow ischaemia was imposed for 10 min. The
temperature of the hearts in these two phases was kept
constant at 378C by immersion in warm Tyrode’s solution
with a pH of 7.4. Myocardial reperfusion was established
at constant coronary flow of 5 mlrmin for the next 15
 .min, whereafter work phase W was performed 20 min2
under conditions identical to those of W .1
The following experimental groups were investigated:
 .  .1 ischaemia-control no application of platelets, ns8 ;
 . 2 platelets application of platelets during low-flow per-
.  . fusion, ns8 ; 3 supernatant application of supernatant
of thrombin-stimulated platelets during low-flow perfu-
.  . sion, ns5 ; 4 lamifiban application of platelets during
low-flow perfusion in the presence of 1 mM lamifiban,
Fig. 1. Schematic presentation of the standard experimental protocol.
Hearts performed volume–pressure work for 20 min each at the begin-
ning and at the end of the protocol. After work phase W , the coronary1
 .system was perfused at constant volume in a low-flow phase 1 mlrmin ,
 . followed by a global ischaemia no flow and a reperfusion phase 5
.mlrmin . In the 15th min of the low-flow phase, a platelet bolus was
 .applied 1 ml in 60 s, 100000rml perfusate . Coronary effluent and
epicardial transudate were sampled during the periods indicated in the
figure. During low-flow perfusion, endothelium was temporarily stimu-
lated with thrombin. AF, aortic flow; CF, coronary flow; ET, ejection
time; HR, heart rate; L, effluent sample for lactate and pyruvate analysis.
.  .ns5 ; and 5 time-control hearts, perfused with 5 mlrmin
coronary flow for 45 min without inducing ischaemia
 .ns5 ; W and W being performed as in the other cases.1 2
With the exception of the time-control group, all hearts
 .were stimulated with thrombin 0.3 Urml from the 6th to
the 15th min of the low-flow phase.
In the 15th min of low-flow perfusion a 1 ml bolus of
 .platelets suspended in Tyrode’s solution 100 000rml was
applied over 1 min into the coronary system via the aortic
cannula with an infusion pump. To keep coronary flow
constant during infusion of platelets, perfusion with
Krebs–Henseleit buffer was stopped for that time. Previ-
ous experience had shown that platelet adhesion in our
experimental setting is facilitated by reduced flow rate.
To differentiate the effect of platelet adhesion from that
of platelet degranulation on the performance of heart work
in our ischaemia–reperfusion situation, a group was estab-
lished using supernatant of activated platelets. One ml of
 .platelet suspension 100 000rml in Tyrode’s solution was
stimulated with 0.3 Urml human thrombin for 10 min.
Platelets were then pelleted for 10 min at 13 000=g and
the resultant supernatant was infused during low-flow per-
fusion in the identical manner as platelet suspensions 1 ml
.in 60 s .
Haemodynamic variables that were determined at the
end of W and W were coronary and aortic flow, sponta-1 2
neous heart rate and ejection time of stroke volume. Exter-
nal heart work the sum of pressure–volume work and
.acceleration work was calculated from these variables
w x13 . Because preload and afterload were held constant for
all preparations during phases of work, changes in cardiac
performance were reflected largely as alterations in cardiac
output. Recovery of external heart work was defined as
postischaemic compared to preischaemic external heart
work, each at 20 min, and expressed in percent.
 .In the reperfusion period epicardial fluid transudate
was collected from the apex of the hearts over 5 min
 .6th–10th min of reperfusion . Transudate formation re-
flects net fluid passage across the vessel walls in the
coronary bed.
As a measure of the severity of myocardial ischaemia,
cardiac lactate release and pyruvate consumption were
measured each time in the 20th min of W and W , the1 2
14th min of the low-flow perfusion phase and the 5th min
of reperfusion. Lactate and pyruvate in the coronary efflu-
 .ent aliquots of about 1 ml were determined using HPLC
w x14 . Pyruvate consumption and lactate release were calcu-
lated as follows:
Pyruvate consumptions pyruvate in perfusate
ypyruvate =perfusion rate;.in effluent
Lactate releases lactate =perfusion rate.in the effluent
The ratio of lactate production to pyruvate consumption
was then calculated, because this quotient emphasises
anaerobic metabolism.
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2.6. Experimental protocol for exclusi˝e measurements of
transudate formation
To study the formation of transudate in the reperfusion
phase in the course of time, the volume-constant reperfu-
sion phase was extended from 15 to 30 min, i.e. no second
work phase was performed. From the 6th to the 30th min
of reperfusion, the formation of transudate was measured
in intervals of 5 min. Values were expressed as mlrmin
for the corresponding interval. Four groups of hearts ns6
.  . per group were investigated: 1 ischaemia-control no
.  .  8platelets were applied ; 2 platelets 10 washed platelets
.were infused in the low-flow phase as described above ;
 . 3 fibrinogen to check the influence of fibrinogen se-
creted by platelets on transudate formation, human fibrino-
gen type I in a concentration of 2 mM was infused instead
of the platelet suspension, but in the same manner 1 ml in
..  .1 min in the 15th min of low-flow perfusion ; and 4
Lamifiban lamifiban, a non-peptide agent with highly
selective binding to RGD-recognising receptor sequences,
tested by applying a concentration equimolar to that of
.  .fibrinogen . All hearts received thrombin 0.3 Urml in
the above-described manner.
2.7. Adhesion measurements
During low-flow perfusion a 1-ml bolus of platelets
 .suspended in Tyrode’s solution 100 000rml was applied
into the coronary system over 1 min. To quantify the
 .number of platelets leaving the coronaries platelet output ,
coronary effluent was collected continuously during the 60
s of bolus application and in the following 240 s. Pilot
studies had shown that only a negligible number of the
 .applied platelets -1% emerged after such a 300-s sam-
pling period. Coronary effluent was sampled in ice-cold
 .10% formaldehyde solution end concentration 1–2% to
fix cells for counting and flow cytometric analysis. Imme-
diately before each intracoronary application, a test bolus
 .of platelets of equal volume and duration 1 ml in 60 s
was sampled to determine the number of cells actually
 .leaving the syringe platelet input . The percentage of
platelets adherent to the endothelium was calculated as
follows:
Adhesion % .
s 1y platelet outputrplatelet input =100 . .
To test the involvement of the platelet adhesion molecule
GPIIbrIIIa in the interaction with the coronary endothe-
lium, lamifiban in a concentration of 1 mM was added to
the platelet suspension 10 min prior to intracoronary infu-
 .sion. The IC for lamifiban in ADP-induced 10 mM50
w xplatelet aggregation is 87 nM 15 . In in vitro experiments,
lamifiban showed very potent anti-aggregatory effects at
w xthe concentration of 1 mM 16 .
2.8. Monoclonal antibodies
Mouse anti-human CD41a Camon, Wiesbaden, Ger-
.many , labelled with FITC, detects the GPIIbrIIIa com-
plex in its resting and activated forms.
Mouse anti-human CD62P Harlan Sera-Lab, Crawley
.Down, UK , labelled with R-PE, recognises the a-granule
membrane glycoprotein P-selectin.
Mouse anti-human CD42b Southern Biotechnology
.Associates, Birmingham, USA , labelled with FITC, binds
to the GPIb molecule, which is a von Willebrand’s factor-
dependent adhesion receptor.
2.9. Flow cytometry
Formalin-fixed platelets of the test bolus and of the
coronary effluent were analysed in a FACScan flow cy-
 .tometer Becton Dickinson, San Jose, USA for glyco-
Table 1
 .  .Initial W and postischaemic W haemodynamic values of hearts successively subjected to 20 min of low-flow ischaemia, 10 min of global ischaemia1 2
and 15 min of reflow
y1 .  .  .  .Group Coronary flow mlrmin Aortic flow mlrmin Heart rate min EHW mJrmin
Time-control W 9.0"0.3 49.1"2.7 245"6 400"201
bTime-control W 8.0"0.2 46.5"3.6 232"3 370"252
Ischaemia-control W 9.4"0.4 50.2"1.6 245"5 410"101
a,bIschaemia-control W 6.2"0.4 32.3"2.0 232"6 260"202
Platelets W 10.5"0.3 49.9"3.0 244"3 410"201
a a,bPlatelets W 7.8"0.5 23.7"4.3 226"6 210"302
Supernatant W 9.6"0.5 48.7"2.8 232"6 400"201
a,bSupernatant W 7.8"0.3 34.7"3.6 223"5 290"302
Lamifiban q platelets W 9.1"0.1 49.6"3.6 245"7 400"301
a,bLamifiban q platelets W 6.7"0.2 31.9"2.6 228"7 260"202
The following boli were applied in the 15th min of low-flow perfusion: ischaemia-control, Tyrode’s solution; platelets, 108 washed platelets; supernatant,
the supernatant of 108 thrombin-stimulated platelets; lamifiban, 108 washed platelets plus 1 mM lamifiban. The time-control group was not exposed to
 .ischaemia, but perfused for the same time period with a coronary flow of 5 mlrmin. Values are means"s.e.m. ns5–8 . EHW, external heart work.
aP -0.05 vs. time-control group.
b  .P -0.05 vs. the W value of the corresponding group paired t-test .1
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protein expression by using labelled monoclonal antibod-
ies: anti-GPIIbrIIIa, anti-P-selectin and anti-GPIb. In gen-
eral, samples containing about 5=106 platelets were cen-
trifuged at 1200=g for 15 min and the supernatant was
discarded. Platelets were resuspended in 100 ml Cellwash
and incubated 15 min after the addition of 5 ml of mono-
clonal antibody. Two ml of Cellwash were then added for
dilution of the antibodies and platelets were centrifuged
again at 1200=g for 15 min. The pellet was resuspended
in 500 ml Cellwash and immediately analysed in the flow
cytometer. Antibody binding was expressed as relative
mean particle fluorescence intensity of total platelet popu-
lation and was used as a quantitative measure of glyco-
protein surface expression before and after coronary pas-
sage. For each measurement, negative controls were per-
formed, in which binding of non-specific monoclonal anti-
bodies labelled with FITC or PE to platelets fixed after
coronary passage was assayed.
2.10. Electron microscopy
To evidence adherence of platelets and to characterise
the location of platelets in the coronary system after
platelet application in the low-flow phase, electron mi-
croscopy of guinea pig hearts was performed. At the end
of the low-flow phase these hearts were perfused with 3%
 .glutaraldehyde pH 7.4 at 4 mlrmin for 15 min. After-
wards, both atria were removed and the ventricles were cut
into four pieces. These were fixed in 3% glutaraldehyde
for 2 h and then stored in 1% glutaraldehyde until pro-
cessed further. A 2-h postfixation episode in 2% OsO was4
 .Fig. 2. Recovery of external heart work EHW . The left column shows
the time-control hearts which were not subjected to ischaemia. The
ischaemia-control group was subjected successively to low-flow and
global ischaemia. After application of 108 washed platelets, recovery of
EHW was significantly impaired, but not after infusion of supernatant of
thrombin-stimulated platelets or of washed platelets in the presence of 1
mM lamifiban. ) P -0.05 vs. all other groups; aP -0.05 vs. time-control
group. Values are means"s.e.m., ns5–8.
 .Fig. 3. Transudate epicardial fluid was collected from the apex of the
 .heart over a 5-min period in the reperfusion phase 6th–10th min . The
time-controls were perfused at constant volume without inducing is-
chaemia. The ischaemia-control group was subjected to low-flow and
global ischaemia. After application of either 108 washed platelets, the
supernatant of 108 thrombin-stimulated platelets or 1 mM lamifiban plus
108 platelets in the low-flow phase the formation of transudate was
)significantly decreased in comparison to the ischaemia-control P -
.0.05 . Values are means"s.e.m., ns5–8.
followed by dehydration in a series of graded ethanols and
embedding in Araldite. For orientation, 1-mm-thick sec-
tions were stained with Toluidine blue. Ultrathin sections
were cut on a Reichert ultramicrotome, contrasted for 5
min with uranylacetate and lead citrate, and viewed in a
Philips CM 10 electron microscope.
Fig. 4. Time course of transudate formation in the extended reperfusion
 .phase 30 min . Transudate was sampled in 5-min periods. Application of
8  .  .10 washed platelets, fibrinogen 2 mM , or lamifiban 2 mM in the
low-flow phase reduced the production of transudate after reflow in a
statistically significant and long-lasting manner. Values are means"
s.e.m., ns6 per group. ) P -0.05 vs. the control group.
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 .Fig. 5. Time course of coronary perfusion pressure mmHg in the
 .extended reperfusion phase 30 min . A slight increase over the course of
time is visible in all groups, but no statistically significant differences
were detectable between groups. Values are means"s.e.m., ns6 per
group.
2.11. Statistical methods
The results are expressed as means"s.e.m. For com-
parisons between two groups, Student’s t-test was used.
For comparison of several groups, analysis of variance
 .ANOVA was first performed to detect a possible overall
difference. Whenever a significant effect was obtained, we
performed multiple comparison tests between the groups
using Student–Newman–Keul’s test Sigma Stat 1.0, Jan-
.del . Differences between data were considered significant
at P-0.05.
3. Results
3.1. Reco˝ery of external heart work and adhesion of
platelets
Intracoronary adhesion of platelets was 16.7"2.4%
under low-flow conditions in the platelet group. In the
presence of 1 mM lamifiban, the adhesion of platelets was
reduced to 10.6"2.3%, although not to a statistically
significant extent. Adhesion of platelets in hearts not ex-
posed to low-flow ischaemia amounted to about 3% data
.not shown .
The pre- and postischaemically measured haemody-
namic data of the working hearts are shown in Table 1.
The performance of time-control hearts proved to be sta-
ble. EHW was reduced about 25% by successively impos-
 .ing low-flow and global ischaemia Fig. 2 . Application of
 8.platelets 10 during the low-flow phase reduced EHW to
a statistically significant extent, recovery being about half
that of time-controls. On the other hand, application of the
supernatant of 108 platelets prestimulated with thrombin
gave a recovery of EHW similar to the ischaemia-control
 .group Fig. 2 . In the presence of lamifiban, the reduced
 .percentage of adherent platelets see above was no longer
able to measurably impair cardiac function, giving a recov-
ery of EHW as good as the ischaemia-control group.
3.2. Transudate formation
Formation of transudate on the epicardial surface of the
isolated heart is related to endothelial integrity and coro-
nary perfusion pressure. Transudate formation measured in
 .time-control hearts perfused at constant volume 5 mlrmin
was 130"14 mlrmin over a 5-min sampling period. This
value was elevated in hearts subjected to the ischaemia–re-
perfusion protocol, amounting to 180"23 mlrmin from
the 6th to the 10th min of reperfusion. Infusion of either
platelets, platelets plus lamifiban, or the supernatant of
stimulated platelets in the low-flow phase led to a highly
significant reduction of transudate formation as measured
between the 6th and the 10th min of reperfusion versus the
 .ischaemia-control group Fig. 3 .
With regard to the time course of transudate production
in the extended reperfusion phase, the data in Fig. 4
demonstrate an immediate and long-lasting inhibitory ef-
fect of platelet application on capillary leakage. Until the
20th min of the reperfusion phase, transudate formation in
the platelet, the fibrinogen and the lamifiban group re-
mained significantly reduced in comparison to the is-
chaemia-control group, with no differences between the
three interventions. After the 20th min of reperfusion,
there was still a tendency towards reduced transudate
formation in the three treatment groups, but statistical
significance was lost. This suggests a gradual loss of the
Table 2
Ratio of lactate production to pyruvate consumption
 .  .  .  .Group W 20th min Low-flow 14th min Reperfusion 5th min W 20th min1 2
a a aIschaemia-control 0.7"0.2 14"1.5 4.0"0.5 2.1"0.1
a a aPlatelets 0.7"0.1 13"0.7 5.1"0.9 1.7"0.4
a a aSupernatant 0.8"0.1 12"0.8 4.2"0.5 1.8"0.2
 .Coronary effluent was analysed for lactate and pyruvate by HPLC. Values are means"s.e.m. ns5–8 . No statistically significant differences between
the groups were detected in any perfusion phase.
aP -0.05 vs. the value in W of the corresponding group.1
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 .  .  .Fig. 6. Two sections of a guinea pig heart fixed after application of human platelets, as viewed by electron microscopy 1:17700 . One A and two B
 .adherent platelets are located in a coronary capillary vessel surrounded by myocardium B . The adherent human platelets still contain their a- and dense
granula. No aggregate formation by platelets was visible.
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sealing actions on capillary leakage. Interestingly, transu-
date formation increased in parallel to the perfusion pres-
 .sure see Fig. 5 over the extended reperfusion period, in
all groups.
3.3. Coronary perfusion pressure
 .Coronary perfusion pressure CPP after 12 min of
 .low-flow perfusion 1 mlrmin was in the order of 4–6
mmHg and not significantly different among the groups.
CPP did not change after application of the platelet bolus.
In the subsequent reperfusion phase, CPP rose continu-
 .ously from values means of 20–25 mmHg in the 5th min
 .to 35–40 mmHg in the 30th min Fig. 5 . However, at no
time were there statistically significant differences between
the groups.
3.4. Production of lactate and consumption of pyru˝ate
Lactate release in W averaged about 1 mmolrmin and1
rose significantly in each group to around 2 mmolrmin in
W . During low-flow perfusion release was in the range2
 .means of 2.6–3.0 mmolrmin and decreased to 1.3–2.3
mmolrmin 5 min after the start of reperfusion. There were
no statistically significant differences between groups.
Consumption of pyruvate in W averaged 1.5 mmolrmin1
and decreased slightly, but significantly, in each group to
around 1 mmolrmin in W . During low-flow perfusion,2
pyruvate consumption decreased to 0.2 mmolrmin and
increased again to about 0.4 mmolrmin in the 5th min of
 .reperfusion no significant differences between the groups .
The ratio of lactate production to pyruvate consumption
revealed a strongly anaerobic metabolic situation of the
 .hearts during low-flow perfusion ratio 12–14 and reper-
 . fusion ratio 4–5 in comparison to W and W ratio1 2
.0.7–2.1 , but, again, the groups showed no statistically
 .significant differences see Table 2 .
3.5. Platelet surface glycoproteins
Measurements were performed of surface glycoproteins
 .GPIIbrIIIa, P-selectin and GPIb of platelets before and
after passage of the coronary system. Means"s.e.m. of
the relative immunofluorescence intensity beforerafter
coronary passage were as follows: GPIIbrIIIa, 140"
12r122"14; P-selectin, 48"4r42"3; GPIb, 30"
2r27"2. Thus, a decrease of about 10% of the relative
immunofluorescence intensity during coronary passage was
detected for all three glycoproteins. For GPIb and
GPIIbrIIIa, but not for P-selectin, the decrease attained
 .statistical significance paired t-test .
3.6. Electron microscopy
Of the inspected coronary vessels, 90–95% were totally
free of platelets. In the remaining 5–10% of the vessels,
mainly single and, very occasionally, groups of two or
 .three adherent platelets were found Fig. 6 . Larger aggre-
gates were not encountered. Adherent platelets did not
occlude the vessel lumen, in any case. Interestingly, adher-
ent platelets were located in capillaries and small venules,
whereas arterioles were free of platelets. Granula contents
were still visible in most of the adherent platelets.
4. Discussion
In this study of isolated guinea pig hearts, sequential
low-flow ischaemia and global ischaemia followed by
reperfusion resulted in a marked decrease in performance
of external heart work. The cardiac dysfunction was signif-
icantly more pronounced after application of just 108
washed human platelets in the low-flow phase, about 17%
of which were sequestered in the coronary microvascula-
ture. There was no evidence of actual coronary occlusion
by platelets. These results demonstrate that platelet adhe-
sion to the coronary endothelium in a situation of myocar-
dial ischaemia can impair recovery of heart performance.
In contrast, degranulation of platelets may have beneficial
effects on the integrity of the coronary endothelium in the
reperfusion situation. This was evidenced by a quantita-
tively identical reduction in net coronary leak of hearts
treated either with platelets or with the supernatant of an
equal number of thrombin-stimulated platelets. Release of
fibrinogen from platelets seems to contribute in part to this
cardioprotective effect, because it was mimicked both by
fibrinogen and by lamifiban, a non-peptide RGD sequence
analogon.
The use of human platelets instead of guinea pig platelets
 .in our xenogenic model offers several advantages: 1
monoclonal antibodies against surface glycoproteins are
available for human platelets, not for those of guinea pigs;
 .2 using human blood, we were able to reduce the number
of animals required for the experiments substantially, as no
 .blood donor animals were needed; 3 the influence of
drugs, e.g., lamifiban, on human platelets puts our experi-
mental setting closer to the clinical situation, our ultimate
point of interest. Although caution may be warranted with
respect to the absolute extent of platelet adhesion seen, in
previous studies with granulocytes, we have already
demonstrated that a qualitatively identical sequestration
occurs after infusion of guinea pig or human granulocytes
w xin the isolated guinea pig heart 17,18 .
4.1. Platelet adhesion
 7.About 17% corresponding to 1.7=10 of the platelets
applied into the coronary system during low-flow perfu-
sion did not re-emerge from the hearts.
There are several lines of evidence that adhesion, but
not aggregation, of platelets in the coronary system is the
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relevant mechanism for this input–output difference of
platelets.
 .1 Coronary perfusion pressures were not significantly
different between groups before and after application of
platelets, thus ruling out large-scale capillary plugging by
platelet aggregates. In a previous study, we were able to
demonstrate that 10-mm diameter microspheres were al-
 .most completely retained 98% in the capillary system of
isolated guinea pig hearts and led to an irreversible in-
crease in coronary resistance, whereas 5-mm diameter
microspheres were not retained and did not elevate perfu-
w xsion pressure 17 .
 .2 Lamifiban at 1 mM, a concentration that inhibited
platelet aggregation via GPIIbrIIIa in-vitro completely
 .data not shown , did not reduce platelet adhesion to a
significant extent. This result is in accordance with studies
by others demonstrating that adhesion mechanisms besides
those involving GPIIbrIIIa, mainly the interaction of GPIb
with von Willebrand’s factor, are able to mediate platelet
w xadhesion to the coronary endothelium 19,20 .
 .3 Electron microscopy of hearts after platelet adhesion
revealed adherent platelets in about 5–10% of the ob-
served capillaries, but no aggregate formation or capillary
plugging. Location of adherent platelets in the capillary
w xsystem has also been shown in isolated rat hearts 10 .
After coronary passage, platelet glycoproteins
GPIIbrIIIa, P-selectin and GPIb each showed a decline of
about 10% in their relative immunofluorescence intensity
in comparison with the platelets tested before intracoro-
nary application. This uniform decrease is taken as an
indication that mainly preactivated platelets with a high
expression of glycoproteins became adherent. Activation
of platelets during the short time of coronary passage
 .-60 s does not seem to occur, otherwise an increase in
GPIIbrIIIa and P-selectin expression would be expected.
Interestingly, adherence of about 1.7=107 platelets in
the coronary system was sufficient to significantly impair
cardiac output after ischaemia and reperfusion 49% recov-
.ery vs. 64% without platelets . The reduction of the exter-
nal heart work in W of the platelet group was mainly due2
to a dramatic fall of aortic flow of over 50% in comparison
to W . Coronary flow was only reduced by about 30%, a1
decline that was also detected in the ischaemia-control
group. Some previous studies have described cardioprotec-
tive effects of washed platelets of rats. These protective
effects were attributed to enhancement of NO production,
release of adenosine from platelets and scavenger capabili-
w xties of the platelet glutathione redox cycle 10–12 , i.e.
actions that should lead to coronary dilatation. Moreover,
in contrast to our present investigation, the platelets were
present before induction of ischaemia and for the entire
reperfusion period. In our experiments, platelet infusion
occurred only during 1 min of low-flow perfusion, thus
making it very unlikely that relevant scavenger effects of
platelets could still be exerted in the reperfusion phase.
Furthermore, in the studies reporting cardioprotection, the
hearts were perfused under normovolaemic conditions G4
.mlrmin coronary flow and then subjected to global is-
chaemia. Pilot experiments in our group have shown that
relevant adherence of washed platelets only occurs under
w xconditions of reduced flow. Rosen et al. 21 demonstrated¨
in an isolated rabbit heart model that the presence of
washed human platelets in a situation of coronary artery
occlusion prevented recovery of contractility on reperfu-
sion and enlarged the area of infarction due to adhesion of
platelets in capillaries near the area at risk. In these
experiments, platelets were infused during the period of
ischaemia and washed out before the occlusion was re-
leased.
w xAlloatti et al. 8 have reported that perfusion of isolated
rabbit hearts with autologous platelets plus platelet-activat-
ing factor results in reduction of contractile force. In our
system, thrombin was used as stimulating factor to induce
thrombogenic properties of the endothelium externalisa-
tion of von Willebrand’s factor, expression of platelet-
. w xactivating factor 22 . Studies that have demonstrated
beneficial effects of platelets did not use any exogenous
stimuli. This might be another explanation for the dis-
crepant results.
The application of platelets in the presence of 1 mM
lamifiban reduced platelet adhesion to 10.6"2.3% in
 .comparison with the control group 16.7"2.4% , which
was not statistically significant. Nevertheless, functional
recovery of hearts in the platelet plus lamifiban group was
significantly better. It should be borne in mind that, in
these hearts, about 6–7=106 platelets less became adher-
ent. Assuming a non-linearity between number of adherent
platelets and functional infringement or a minimal require-
ment of adherence, this could be cause enough for im-
proved recovery. In addition, the thromboxane A forma-2
tion by stimulated platelets is reportedly reduced about
w x20% by lamifiban 16 . Furthermore, lamifiban itself –
applied without platelets – had beneficial effects on the
coronary endothelium reduced transudate formation in the
.reperfusion phase . Indeed, the parallel infusion of platelets
plus lamifiban in the low-flow phase led to the lowest
transudate formation in the early reperfusion phase seen in
 .any group 38"8 vs. 71"16 mlrmin for platelets alone .
The mechanism by which a small number of adherent
platelets infringes myocardial function after ischaemia and
reperfusion is intriguing, but remains unclear. Ongoing
conversion of the platelet membrane constituent arachi-
donic acid to cardiodepressants, such as the isoprostanes or
w xthromboxane A 14 presents a likely cause. In animal2
studies, thromboxane receptor antagonists have been shown
w x w xto be antiarrhythmic 23 and to reduce infarct size 24 .
4.2. Transudate formation
Ischaemia–reperfusion has been shown to cause func-
w xtional coronary microvascular injury 1 , the increase in
permeability being proportional to both the duration and
 at U
niversitaetsbibliothek M
uenchen on January 24, 2013
http://cardiovascres.oxfordjournals.org/
D
ow
nloaded from
 
( )B. Heindl et al.rCardio˝ascular Research 38 1998 383–394392
severity of ischaemia. Since myocardial oedema is known
w xto depress contractile function 25 , this seemed to be an
attractive explanation also for the deleterious action of
w xadherent platelets. Indeed, Kupatt et al. 4 described a
progressive increase of transudate formation in isolated
guinea pig hearts induced by postischaemic intracoronary
application of human granulocytes. The isolated perfused
heart model allows a direct measurement of net transmural
fluid passage in the entire coronary bed in the form of
transudate flow. To our great surprise, the infusion of
platelets in the low-flow phase in our experimental system
led to significantly decreased – and not increased – forma-
tion of transudate in the reperfused hearts, even when
reperfusion was extended to 30 min. The application of
supernatant of thrombin-stimulated platelets had the identi-
cal effect. Thus, degranulation of platelets seems to liber-
ate a long-acting, permeability-reducing principle.
Formation of glycoprotein-rich microparticles after
stimulation of washed platelets with thrombin has been
w xdemonstrated 26 . Binding of these platelet membrane
particles to the coronary endothelium could have elicited a
sealing effect. However, we were not able to demonstrate
microparticle formation in our experimental setting data
.not shown , probably due to the short contact period
between thrombin and platelets during coronary passage
 .20–30 s and the relatively low thrombin concentration
 .0.3 Urml .
For labile substances released by activated platelets,
like ADP, adrenalin or serotonin, one would expect a brief
effect on vascular permeability. However, adherent platelets
could continuously release such agonists. In the platelet
group, the correlation coefficient between transudate for-
mation from the 6th to the 10th min of reperfusion and the
number of adherent platelets was 0.27 statistically in-
.significant . Thus, the transudate-lowering effect seems to
be independent of the percentage of adherent platelets. In
other words, continuous production of labile factors by
these platelets does not seem to invoke the protective
effect on the endothelium derived from a bolus of platelets.
The long-acting nature of the permeability-reducing effect
 .still detectable 35 min after application of platelets drew
our attention to protein components known to be liberated
from activated platelets, foremost to fibrinogen. According
to our results, a single, preischaemic bolus application of
fibrinogen, but also one of lamifiban, had the same sup-
pressant effect on transudate formation as did platelets or
the supernatant of platelets. Our chosen concentration of
0.6 mgrml fibrinogen corresponded to about 20% of the
level found in human plasma.
With regard to the time course of transudate production
in the extended reperfusion phase, all three sealing actions
 .platelets, fibrinogen, lamifiban were maintained relative
to the ischaemia-controls, but the absolute rate of transu-
date formation increased with time in all groups. Perme-
ability of water and small hydrophilic solutes is basically
influenced by intra- and extravasal hydrostatic and oncotic
pressures and by the endothelial barrier. In our model,
venous and lymphatic pressure were kept constantly low,
as both fluids drained freely from the heart. Oncotic
pressure was very low as the perfusion buffer was devoid
of proteins. The only variable force was, therefore, the
coronary perfusion pressure. In our study, perfusion pres-
sure showed a slight, but continuous increase over the
reperfusion phase, without any significant differences be-
tween groups at any time of the perfusion protocol. Thus,
observed differences of the net fluid transport across the
vascular wall at any one time seem to reflect the integrity
of the endothelial layer.
The fact that lamifiban reduced transudate formation in
the reperfused heart to the same extent as fibrinogen
implicates a common mechanism for these two molecu-
larly quite different agents large peptide vs. small non-
.peptide and excludes a purely oncotic action of fibrino-
gen. Interestingly, both have affinity to receptors recognis-
ing the RGD-peptide sequence. Pertinently, in endothelial
cell cultures, it has been shown that fibronectin, which also
contains an RGD sequence, contributes to the maintenance
w xof the barrier 27 . During application of the fibrinogen
bolus as well as during stimulation of platelet secretion
 .thrombin 0.3 Urml was present. This might have led to
processing of fibrinogen to fibrin. Therefore, the observed
suppressant effect on transudate formation could be due to
fibrinogen or fibrin actions or both, since both contain the
w xRGD sequence 28 . Cross-linking of fibrin monomers and
formation of a fibrin network seems to be unlikely, owing
to the lack of factor XIII.
Two adhesion molecules might be of interest in this
 .context: a b -integrin vitronectin receptor and the inter-v 3
cellular adhesion molecule ICAM-1. For both, the exis-
tence on the luminal surface of endothelial cells has been
w x w xshown 29–32 . Hicks et al. 32 demonstrated on isolated
veins that fibrinogen is able to influence vasomotion by
binding to ICAM-1. However, the RGD sequence appar-
ently is not involved in the interaction of fibrinogen with
w xICAM-1 33,34 . No data are available on fibrin binding to
w xICAM-1. Nevertheless, D’Souza et al. 35 were able to
show that an RGD peptide reduced the binding of fibrino-
gen to unstimulated ICAM-1, thus suggesting an interac-
tion of RGD sequence containing peptides with the fibrino-
gen receptor part of ICAM-1. Fibrinogen and fibrin are
able to bind to the vitronectin receptor and this binding can
w xbe efficiently blocked by RGD-containing peptides 28 .
Fibrinopeptides had no influence on the binding of fibrin
to the vitronectin receptor. Binding of RGD-containing
peptides to the vitronectin receptor of arterioles mediated
w xvasodilation 36 . In view of these multiple actions, fib-
rinogen, normally present in plasma or in locally high
concentrations after degranulation of platelets, or fibrin
produced in the presence of thrombin, may partially allay
ischaemia–reperfusion injury in the heart by interacting
with ICAM-1 or the vitronectin receptor on the luminal
surface of coronary endothelial cells.
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In conclusion, platelet adhesion to the coronary en-
dothelium in a situation of myocardial ischaemia and
reperfusion can further induce cardiac dysfunction. In con-
trast, degranulation of platelets produced beneficial effects
on the integrity of the coronary endothelium in isolated
hearts perfused with crystalloid buffer; the active principle
most likely being fibrinogen. Due to high plasma fibrino-
gen already present in-vivo, this endothelial-protective ef-
fect of fibrinogen released by platelets may only play a
minor role. This would place even more emphasis on the
deleterious effects of platelets in vivo.
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